# Analgesic efficacy of an opioid-free postoperative pain management strategy versus a conventional opioid-based strategy following laparoscopic radical gastrectomy: an open-label, randomized, controlled, non-inferiority trial

**Authors:** Zhimin Lin, Zhongbiao Chen, Yongliang Li

PMC · DOI: 10.1186/s12957-023-03298-x · 2024-02-15

## TL;DR

This study compares an opioid-free pain management method with traditional opioid use after stomach surgery and finds both are equally effective for pain control.

## Contribution

The study provides clinical evidence that a continuous opioid-free STAPB is non-inferior to conventional opioid-based pain management after laparoscopic radical gastrectomy.

## Key findings

- There were no significant differences in pain scores between the opioid-free and conventional groups at rest and during movement.
- The opioid-free group showed faster postoperative recovery, including quicker bowel movement and food intake.
- The opioid-free method had lower rates of postoperative nausea and vomiting compared to the conventional group.

## Abstract

In patients undergoing laparoscopic radical gastrectomy, the use of subcostal transversus abdominis plane block (STAPB) for completely opioid-free postoperative pain management lacks convincing clinical evidence.

This study included 112 patients who underwent laparoscopic radical gastrectomy at the 900TH Hospital of the Joint Logistics Support Force from October 2020 to March 2022. Patients were randomly divided into (1:1) continuous opioid-free STAPB (C-STAPB) group and conventional group. In the C-STAPB group, 0.2% ropivacaine (bilateral, 20 ml per side) was injected intermittently every 12 h through a catheter placed on the transverse abdominis plane for postoperative pain management. The conventional group was treated with a conventional intravenous opioid pump (2.5 μg/kg sufentanil and 10 mg tropisetron, diluted to 100 ml with 0.9% NS). The primary outcomes were the accumulative area under the curve of the numeric rating scale (NRS) score at 24 and 48 h postoperatively at rest and during movement. The secondary outcomes were postoperative recovery outcomes, postoperative daily food intake, and postoperative complications.

After exclusion (n = 16), a total of 96 patients (C-STAPB group, n = 46; conventional group, n = 49) were included. We found there were no significant differences in the cumulative AUC of NRS score PACU-24 h and PACU-48 h between the C-STAPB group and conventional group at rest [(mean difference, 1.38; 95% CI, − 2.21 to 4.98, P = 0.447), (mean difference, 1.22; 95% CI, − 6.20 to 8.65, P = 0.744)] and at movement [(mean difference, 2.90; 95% CI, − 3.65 to 9.46; P = 0.382), (mean difference, 4.32; 95% CI, − 4.46 to 13.1; P = 0.331)]. The 95% CI upper bound of the difference between rest and movement in the C-STAPB group was less than the inferior margin value (9.5 and 14 points), indicating the non-inferiority of the analgesic effect of C-STPAB. The C-STAPB group had faster postoperative recovery profiles including earlier bowel movement, defecation, more volume of food intake postoperative, and lower postoperative nausea and vomiting compared to conventional groups (P < 0.001).

After laparoscopic radical gastrectomy, the analgesic effect of C-STAPBP is not inferior to the traditional opioid-based pain management model.

ChiCTR2100051784.

## Linked entities

- **Chemicals:** ropivacaine (PubChem CID 71273), sufentanil (PubChem CID 41693), tropisetron (PubChem CID 656665)

## Full-text entities

- **Diseases:** pain (MESH:D010146), postoperative complications (MESH:D011183), postoperative nausea and vomiting (MESH:D020250), postoperative pain (MESH:D010149)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10868092/full.md

---
Source: https://tomesphere.com/paper/PMC10868092